LGALS3 and atherosclerosis: In an atherosclerotic plaque visualization study based on positron emission tomography imaging, (Varasteh et al., 2021) explored the feasibility of targeting Gal3 expression to trace atherosclerosis using a zirconium-89 labeled Gal3-F (ab')2 monoclonal antibody.